Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial

NCT05403736 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to examine adherence to cardio-oncology consultation.

Conditions Studied

Interventions

  • OTHER Cardiac Aggressive Risk MitigAtion Plan

Study Locations (1)

California

  • Cancer Clinical Trials Office — Los Angeles

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-10-07
Est. Completion 2023-06-16
Phase NA

Sponsor

Cedars-Sinai Medical Center

360 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05403736

The ClinicalTrials.gov registry entry for NCT05403736 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 360 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention — of which Cardiac Aggressive Risk MitigAtion Plan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05403736 reports 1 study location spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05403736 about?

NCT05403736 is a clinical study titled "Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial". The purpose of this study is to examine adherence to cardio-oncology consultation.

What is the current status of trial NCT05403736?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2022-10-07. Estimated completion is 2023-06-16.

What conditions does trial NCT05403736 study?

This clinical trial studies the following conditions: Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05403736?

The interventions under investigation include: Cardiac Aggressive Risk MitigAtion Plan (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05403736?

This trial is sponsored by Cedars-Sinai Medical Center, which has 360 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05403736 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial